Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

548
Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
548
Pericarditis II: Clinical Features and Diagnostic Tests01:19

Pericarditis II: Clinical Features and Diagnostic Tests

341
Pericarditis is distinguished by inflammation of the pericardium, the fibrous sac that encases the heart. It can be acute, lasting less than six weeks, or chronic, persisting for over three months. Understanding its clinical manifestations and diagnostic findings is crucial for timely and effective management.Clinical ManifestationsWhile pericarditis can be asymptomatic, it usually presents with characteristic symptoms such as:Chest Pain: The most characteristic symptom of pericarditis is chest...
341
Myocarditis II: Clinical Features and Diagnostic Tests01:27

Myocarditis II: Clinical Features and Diagnostic Tests

332
Myocarditis is an inflammation of the heart muscle. The symptoms vary widely, encompassing asymptomatic presentations to severe, acute manifestations.Clinical PresentationAsymptomatic cases: In some instances, myocarditis may be asymptomatic, with the infection resolving without intervention. These cases often go undetected unless discovered incidentally through diagnostic imaging or tests conducted for other reasons.General Early Symptoms: Early symptoms of myocarditis are non-specific and can...
332
Clinical Trials01:16

Clinical Trials

10.8K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
10.8K
Clinical Trials: Overview01:11

Clinical Trials: Overview

5.0K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
5.0K
Statistical Software for Data Analysis and Clinical Trials01:12

Statistical Software for Data Analysis and Clinical Trials

1.6K
Statistical software is pivotal in data analysis and clinical trials by providing tools to analyze data, draw conclusions, and make predictions. These software packages range from simple data management applications to complex analytical platforms, supporting various statistical tests, models, and simulation techniques. Their significance lies in their ability to handle vast amounts of data with precision and efficiency, enabling researchers to validate hypotheses, identify trends, and make...
1.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

On clinical trials with a high placebo response rate.

Contemporary clinical trials communications·2018
Same author

Silencing P2X7 receptor downregulates the expression of TCP-1 involved in lymphoma lymphatic metastasis.

Oncotarget·2015
Same author

Aqueous extracts of Fructus Ligustri Lucide induce gastric carcinoma cell apoptosis and G2/M cycle arrest.

International journal of clinical and experimental medicine·2015
Same author

Association between IL-17F rs763780 polymorphism and susceptibility of asthma: a meta-analysis.

International journal of clinical and experimental medicine·2015
Same author

Probing the Structural Stability of and Enhanced CO2 Storage in MOF MIL-68(In) under High Pressures by FTIR Spectroscopy.

Chemistry (Weinheim an der Bergstrasse, Germany)·2015
Same author

MicroRNA-222 Controls Human Pancreatic Cancer Cell Line Capan-2 Proliferation by P57 Targeting.

Journal of Cancer·2015

Related Experiment Video

Updated: Feb 7, 2026

In Silico Clinical Trials for Cardiovascular Disease
09:09

In Silico Clinical Trials for Cardiovascular Disease

Published on: May 27, 2022

2.3K

A method for testing a prespecified subgroup in clinical trials.

Yang Song1, George Y H Chi

  • 1Clinical Biostatistics, Oncology R&D, Johnson & Johnson Pharmaceutical Research & Development, 920 Route 202, Raritan, NJ 08869, USA. ysong9@prdus.jnj.com

Statistics in Medicine
|February 3, 2007
PubMed
Summary

This study introduces a statistical method for clinical trial subgroup analysis. It enhances power for subgroup efficacy claims while controlling Type I error rates, crucial for regulatory approval.

More Related Videos

Characterizing Exon Skipping Efficiency in DMD Patient Samples in Clinical Trials of Antisense Oligonucleotides
05:16

Characterizing Exon Skipping Efficiency in DMD Patient Samples in Clinical Trials of Antisense Oligonucleotides

Published on: May 7, 2020

7.3K
Enumeration of Major Peripheral Blood Leukocyte Populations for Multicenter Clinical Trials Using a Whole Blood Phenotyping Assay
14:45

Enumeration of Major Peripheral Blood Leukocyte Populations for Multicenter Clinical Trials Using a Whole Blood Phenotyping Assay

Published on: September 16, 2012

15.5K

Related Experiment Videos

Last Updated: Feb 7, 2026

In Silico Clinical Trials for Cardiovascular Disease
09:09

In Silico Clinical Trials for Cardiovascular Disease

Published on: May 27, 2022

2.3K
Characterizing Exon Skipping Efficiency in DMD Patient Samples in Clinical Trials of Antisense Oligonucleotides
05:16

Characterizing Exon Skipping Efficiency in DMD Patient Samples in Clinical Trials of Antisense Oligonucleotides

Published on: May 7, 2020

7.3K
Enumeration of Major Peripheral Blood Leukocyte Populations for Multicenter Clinical Trials Using a Whole Blood Phenotyping Assay
14:45

Enumeration of Major Peripheral Blood Leukocyte Populations for Multicenter Clinical Trials Using a Whole Blood Phenotyping Assay

Published on: September 16, 2012

15.5K

Area of Science:

  • Clinical Trials Methodology
  • Biostatistics
  • Pharmaceutical Research

Background:

  • Investigational treatments often require subgroup analysis for specific patient populations.
  • Efficacy claims for subgroups are vital when overall population tests fail, especially for regulatory and ethical reasons.

Purpose of the Study:

  • To develop a statistical methodology for simultaneously testing overall and subgroup hypotheses in clinical trials.
  • To optimize statistical power for subgroup analyses while rigorously controlling familywise Type I error rates.

Main Methods:

  • A general statistical framework is proposed for hypothesis testing in clinical trials.
  • The methodology incorporates prespecification requirements and ethical/regulatory considerations for subgroup analysis.

Main Results:

  • The proposed method offers optimal power for detecting subgroup treatment effects.
  • It strongly controls the familywise Type I error rate, ensuring statistical validity.

Conclusions:

  • The developed statistical approach provides a robust framework for subgroup analysis in clinical trials.
  • This methodology supports evidence-based decision-making for treatment efficacy in specific patient populations.